Insights into ASX Stocks
Cochlear (ASX: COH): Class Action Hits after 40% Crash, but Nexa Fuels Comeback Bid
Cochlear (ASX: COH) faces a shareholder class action over its FY26 profit forecast, just as its Nexa rollout, fully implantable trials and a November investor day shape the recovery story.
.webp&w=828&q=75)
Northern Star Resources (ASX: NST): A$38.7B Gold Fields Bid Rejected as Elliott Pressure Builds
Northern Star Resources (ASX: NST) has rejected Gold Fields’ A$38.7 billion takeover proposal amid increased pressure from Elliott Investment Management and leadership changes, while continuing to advance KCGM expansion, Hemi development, and its long-term growth strategy.
Megaport (ASX: MP1): AI Clients Pre-Pay A$323M, Turning GPU Bets into Bankable Growth
Megaport (ASX: MP1) secures three AI infrastructure contracts, with customers prepaying about A$323 million, and lifts FY27 revenue and margin guidance as its Latitude.sh compute arm scales alongside a growing network business.
LTR Pharma (ASX: LTP): Where Revenue Growth Must First Survive the Clinical Test
LTR Pharma is moving towards commercialisation, with a targeted ROXUS US launch and SPONTAN Phase III trial. A scenario-based valuation suggests A$2.28 per share, but clinical, regulatory and funding risks remain significant. The chart shows consolidation below resistance.
.webp&w=828&q=75)
BrainChip Holdings(ASX: BRN): Akida Neuromorphic AI Advances Edge Computing Across Strategic Markets
BrainChip (ASX: BRN) is advancing its Akida neuromorphic AI technology through developments in low-power Edge AI processing, strategic partnerships, and applications across healthcare, defence, aerospace, and industrial sectors.
Stakk (ASX: SKK): A Bigger Revenue Base, A New Earnings Story
Stakk (ASX: SKK) is transitioning into a B2B embedded-finance platform, boosted by its US$63m ParaScript acquisition. FY2026 revenue surged 1,098% to A$14.89m, with FY2027 targets of A$55.2m revenue fully contracted, though going concern risk persists.